[144] CareDx, Inc. SEC Filing

Rhea-AI Filing Summary

CareDx, Inc. (CDNA) – Form 144 filing discloses a proposed sale of 10,570 common shares through Morgan Stanley Smith Barney on the NASDAQ. The shares, acquired as restricted stock units on 14 Jun 2025, carry an aggregate market value of $206,326.40, implying an indicative price of roughly $19.53 per share. The transaction is slated to occur on or about 18 Jun 2025. According to the filing, no other sales were made in the past three months, and the sale represents only ~0.02 % of the 55.68 million shares outstanding, suggesting minimal dilution or market impact. The filer certifies awareness of no undisclosed material adverse information and may be relying on a Rule 10b5-1 trading plan. Relationship to the issuer and filer identity were not provided in the excerpt.

Insights

Securities Analyst

TL;DR: Routine insider sale of 10,570 CDNA shares (~0.02% of float); immaterial to valuation.

The Form 144 signals an intended disposal of a small block of CareDx stock worth roughly $206k. Volume is negligible relative to the 55.7 million shares outstanding, so liquidity or price pressure should be minimal. Because the shares derive from recently vested RSUs and the seller attests to no undisclosed negative information, the trade appears to be a standard monetisation event, possibly under a pre-arranged 10b5-1 plan. There are no red flags regarding large-scale insider exit or strategic shifts. I classify the filing as not impactful for fundamental or technical outlook.

Corporate Governance Expert

TL;DR: Small RSU liquidation; governance risk unchanged.

From a governance standpoint, the filing is routine. Rule 144 requires disclosure when insiders sell restricted or control securities; here, compliance appears straightforward. The absence of past-quarter sales and the use of a reputable broker further reduce concern. The certification of no undisclosed adverse information aligns with best practices. Without filer identity or board role, it is impossible to gauge signalling value; however, given the tiny stake, I view this as administratively neutral.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10570	206326.40	55680549	06/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/14/2025	Restricted Stock Units	Issuer			10570	06/14/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many CareDx (CDNA) shares are covered by the Form 144 filing?

The notice covers 10,570 common shares.

What is the aggregate market value of the proposed CDNA share sale?

The filing lists an aggregate value of $206,326.40.

When is the approximate sale date for the CDNA shares?

The shares are expected to be sold on or about 18 June 2025.

What percentage of CareDx’s outstanding shares does the sale represent?

It represents roughly 0.02 % of the 55.68 million shares outstanding.

Which broker is handling the sale of the CDNA shares?

The broker of record is Morgan Stanley Smith Barney LLC.